Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid® both in Combination with Insulin Degludec in Children and Adolescents with Type 1 Diabetes

Mise à jour : Il y a 4 ans
Référence : U1111-1158-1170

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To confirm the effect of treatment with meal-time faster-acting insulin aspart in terms of glycaemic control by comparing it to meal-time NovoRapid®, both in combination with insulin degludec using a non-inferiority approach in children and adolescents with type 1 diabetes


Critère d'inclusion

  • Diabetes Mellitus, Type 1